View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
August 31, 2018

Novo Nordisk invests in glucose binding tech to stay ahead in diabetes market

On 17 August Novo Nordisk announced the complete acquisition of Ziylo, a University of Bristol spinout company, for $800 million.

By GBI Research

On 17 August Novo Nordisk announced the complete acquisition of Ziylo , a University of Bristol spinout company, for $800 million.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

The acquisition gives Novo Nordisk full rights to Ziylo ’s glucose binding molecule technology, allowing it to develop glucose responsive insulins.

Developing glucose responsive insulins has been a key area of focus for Novo Nordisk , as these insulins will help create a safer therapy by eliminating the main risk associated with insulin therapy: hypoglycaemia.

These insulins can also make therapy more effective, as elimination of hypoglycaemia can lead to better metabolic control, thereby reducing the burden of diabetes for people living with the disease.

Regarding the acquisition, the chief executive officer and co-founder of Ziylo , Harry Destecroix, said “Novo Nordisk is the ideal company to maximise the potential of the Ziylo glucose binding molecules in glucose responsive insulins and diabetes applications, and it brings hope of a truly groundbreaking treatment to diabetes patients.”

In the global diabetes care market, Novo Nordisk is the market leader with 27% of the market share.

With the recent acquisition, Novo Nordisk aspires to realise the world’s first glucose responsive insulin, which would help it to stay ahead in the market.

For more insight and data, visit the GBI Research report store.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology